Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/24/2012 | 07:59am CEST

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.
###

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
08/31 DAIICHI SANKYO : ENSURE-AF Data Support the Efficacy and Safety Profile of Daiic..
08/31 DAIICHI SANKYO : Antiepileptic Drug Vimpat® Tablets 50 mg and 100 mg have been l..
08/29 DAIICHI SANKYO : Receives Additional Dosage Regimen Approval in Japan for Long-a..
08/29 DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
08/26 DAIICHI SANKYO : Receives Additional Dosage Regimen Approval in Japan for Long-a..
08/26 DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
08/24 DAIICHI SANKYO : Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban
08/24 DAIICHI SANKYO : Ex-ranbaxy owners oppose award to daiichi
08/11 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
08/11 DAIICHI SANKYO : Patent Issued for Pharmaceutical Composition Containing Diamine..
More news
Sector news : Pharmaceuticals - NEC
12:44a SUMITOMO DAINIPPON PHARMA : Sunovion Pharma to buy Canada's Cynapsus for $624 mi..
08/31 U.S. sues to stop Deere from buying Precision Planting
08/31DJSHIRE : Files 8K - Other Events
08/31DJASTRAZENECA : Agrees to Pay $5.5 Million to Settle Alleged Bribery Probe
08/31DJASTRAZENECA : Agrees to Pay $5.5 Million to Settle Alleged Bribery Probe
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/18 FDA rejects Portola's AndexXa NDA; shares down 18% premarket
07/15 Therapy Focus - Another Try For FGFR Inhibitors
07/14 Amgen and Daiichi Sankyo team up to market biosimilars in Japan
06/01 Nektar Therapeutics inks deal with Daiichi Sankyo for European rights to Onze..
04/26 Aviragen sells portion of Inavir royalty rights for $20M
Advertisement
Financials ( JPY)
Sales 2017 913 800 M
EBIT 2017 -
Net income 2017 67 029 M
Finance 2017 309 117 M
Yield 2017 2,95%
P/E ratio 2017 23,51
P/E ratio 2018 24,18
EV / Sales 2017 1,50x
EV / Sales 2018 1,55x
Capitalization 1 681 420 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 502  JPY
Spread / Average Target 5,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura Vice President-Finance & Accounting Department
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..-4.73%16 303
JOHNSON & JOHNSON16.31%326 855
ROCHE HOLDING LTD.-12.84%214 220
PFIZER INC.8.05%211 570
NOVARTIS AG-10.83%209 772
ASTRAZENECA PLC7.33%174 031
More Results